Research Summary

My research efforts are focused on the development and testing of novel, biologically based therapies for gastrointestinal malignancies, with an emphasis on neuroendocrine tumors (NETs). I am co-chair of the GI Oncology site committee and an active member of the Phase I committee at UCSF. Nationally, I am co-chair of the Neuroendocrine Tumor Task Force of the National Cancer Institute (NCI) Gastrointestinal Steering Committee, a member of the NCCN Neuroendocrine Tumors Guidelines Panel, a member of the Board of Directors for the North American Neuroendocrine Tumor Society (NANETS), and co-chair of the 8th edition AJCC Expert Panel on staging for NETs. I am also study chair for ALLIANCE A021202 (an ongoing randomized Phase II trial of pazopanib vs. placebo in patients with progressive carcinoid tumors). My current research is focused on publishing the results of three completed investigator-initiated Phase II clinical trials in NETs (a. FOLFOX/bevacizumab, b. everolimus plus erlotinib, and c. axitinib), fostering several collaborations with laboratory-based colleagues, and taking advantage of a fully annotated outcomes database (established in 2010 and encompassing 600+ NET patients treated at UCSF since 2004).

Education

University of Wisconsin, B.S., 1985, Biochemistry and Molecular Biology
University of Minnesota, M.D., 1982

Honors & Awards

  • 1982
    Phi Beta Kappa
  • 1985-82
    Vine Scholarship, University of Minnesota
  • 1982
    May Sine Peterson Award, University of Minnesota
  • 1982
    Alpha Omega Alpha
  • 1995-92
    Molecular Medicine Fellowship, University of California San Francisco

Selected Publications

  1. Baxter NN, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Lieu C, Mahmoud N, Morris AM, Ruiz-Garcia E, You YN, Meyerhardt JA. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. J Clin Oncol. 2021 Dec 22; JCO2102538.  View on PubMed
  2. Sun N, Yang Y, Miao H, Redublo P, Liu H, Liu W, Huang YW, Teng PC, Zhang C, Zhang RY, Smalley M, Yang P, Chou SJ, Huai K, Zhang Z, Lee YT, Wang JJ, Wang J, Liang IY, Zhang TX, Zhang D, Liang L, Weiss PS, Posadas EM, Donahue T, Hecht JR, Allen-Auerbach MS, Bergsland EK, Hope TA, Pei R, Zhu Y, Tseng HR, Heaney AP. Discovery and characterization of circulating tumor cell clusters in neuroendocrine tumor patients using nanosubstrate-embedded microchips. Biosens Bioelectron. 2022 Mar 01; 199:113854.  View on PubMed
  3. Kasai Y, Masui T, Nakakura EK, Nakano K, Sato A, Uchida Y, Yogo A, Nagai K, Anazawa T, Hope TA, Kim GE, Whitman J, Le BK, Takaori K, Bergsland EK, Hatano E, Uemoto S. Preoperative risk stratification of lymph node metastasis for non-functional pancreatic neuroendocrine neoplasm: An international dual-institutional study. Pancreatology. 2021 Oct 28.  View on PubMed
  4. Chan DL, Bergsland EK, Chan JA, Gadgil R, Halfdanarson TR, Hornbacker K, Kelly V, Kunz PL, McGarrah PW, Raj NP, Reidy DL, Thawer A, Whitman J, Wu L, Becker C, Singh S. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review. Oncologist. 2021 Aug 03.  View on PubMed
  5. Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, Chan J, Das S, Dickson PV, Fanta P, Giordano T, Halfdanarson TR, Halperin D, He J, Heaney A, Heslin MJ, Kandeel F, Kardan A, Khan SA, Kuvshinoff BW, Lieu C, Miller K, Pillarisetty VG, Reidy D, Salgado SA, Shaheen S, Soares HP, Soulen MC, Strosberg JR, Sussman CR, Trikalinos NA, Uboha NA, Vijayvergia N, Wong T, Lynn B, Hochstetler C. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 07 28; 19(7):839-868.  View on PubMed
  6. Chen KS, Lawhn-Heath C, Behr S, Juarez R, Whitman J, Paciorek A, Nakakura EK, Fidelman N, Feng MU, Bergsland EK, Anwar M. Outcomes after high-dose radiation in the management of neuroendocrine neoplasms. PLoS One. 2021; 16(6):e0252574.  View on PubMed
  7. Pegna GJ, Roper N, Kaplan RN, Bergsland E, Kiseljak-Vassiliades K, Habra MA, Pommier Y, Del Rivero J. The Immunotherapy Landscape in Adrenocortical Cancer. Cancers (Basel). 2021 May 28; 13(11).  View on PubMed
  8. Hörsch D, Anthony L, Gross DJ, Valle J, Welin S, Benavent M, Caplin M, Pavel M, Bergsland E, Öberg K, Kassler-Taub KB, Binder P, Banks P, Lapuerta P, Kulke MH. Long-term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study. Neuroendocrinology. 2021 May 03.  View on PubMed
  9. Chan H, Zhang L, Choti MA, Kulke M, Yao JC, Nakakura EK, Bloomston M, Benson AB, Shah MH, Strosberg JR, Bergsland EK, Van Loon K. Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database. Pancreas. 2021 04 01; 50(4):506-512.  View on PubMed
  10. Mahuron KM, Kasai Y, Javeed ZA, Bergsland EK, Hirose K, Corvera CU, Nakakura EK. Minimally Invasive Surgery for Ileal Neuroendocrine Tumors. J Gastrointest Surg. 2021 Mar 19.  View on PubMed
  11. Dillon JS, Kulke MH, Hörsch D, Anthony LB, Warner RRP, Bergsland E, Welin S, O'Dorisio TM, Kunz PL, McKee C, Lapuerta P, Banks P, Pavel M. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome. J Gastrointest Cancer. 2021 Mar; 52(1):212-221.  View on PubMed
  12. Whitman J, Allen IE, Bergsland EK, Suh I, Hope TA. Assessment and Comparison of 18F-Fluorocholine PET and 99mTc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis. J Nucl Med. 2021 Sep 01; 62(9):1285-1291.  View on PubMed
  13. Yao JC, Strosberg J, Fazio N, Pavel ME, Bergsland E, Ruszniewski P, Halperin DM, Li D, Tafuto S, Raj N, Campana D, Hijioka S, Raderer M, Guimbaud R, Gajate P, Pusceddu S, Reising A, Degtyarev E, Shilkrut M, Eddy S, Singh S. Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms. Endocr Relat Cancer. 2021 Jan 01.  View on PubMed
  14. Maddali MV, Chiu C, Cedarbaum ER, Yogeswaran V, Seedahmed M, Smith W, Bergsland E, Fidelman N, Kennedy JLW. Carcinoid Crisis-Induced Acute Systolic Heart Failure. JACC Case Rep. 2020 Nov; 2(13):2068-2071.  View on PubMed
  15. Saleh M, Bhosale PR, Yano M, Itani M, Elsayes AK, Halperin D, Bergsland EK, Morani AC. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms. Abdom Radiol (NY). 2020 Oct 23.  View on PubMed
  16. Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O'Dorisio TM, Halperin DM, Fishbein L, Eads J, Hope TA, Singh S, Salem R, Metz DC, Naraev BG, Reidy-Lagunes DL, Howe JR, Pommier RF, Menda Y, Chan JA. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas. 2020 08; 49(7):863-881.  View on PubMed
  17. Singh S, Bergsland EK, Card CM, Hope TA, Kunz PL, Laidley DT, Lawrence B, Leyden S, Metz DC, Michael M, Modahl LE, Myrehaug S, Padda SK, Pommier RF, Ramirez RA, Soulen M, Strosberg J, Sung A, Thawer A, Wei B, Xu B, Segelov E. Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines. J Thorac Oncol. 2020 10; 15(10):1577-1598.  View on PubMed
  18. Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR. North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. Pancreas. 2020 07; 49(6):723-728.  View on PubMed
  19. Bodei L, Bergsland E, de Herder WW, Ferone D, Hicks RJ, Hope TA, Kunikowska J, Pavel M, Reidy-Lagunes D, Siveke J, Strosberg J, Dittmer U, Herrmann K. Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns? J Nucl Med. 2020 Aug; 61(8):1094-1095.  View on PubMed
  20. Lou E, Beg MS, Bergsland E, Eng C, Khorana AA, Kopetz S, Lubner S, Saltz L, Shankaran V, Zafar SY. Reply to S. Boutayeb et al. JCO Oncol Pract. 2020 08; 16(8):525.  View on PubMed

Go to UCSF Profiles, powered by CTSI